Helixgate

Helixgate

Uncategorized

Daiichi takes $850M charge, axes facility investment as ADC demand forecast falls

Published

on

While Daiichi Sankyo brought in $13.4 billion in 2025, setbacks forced the company to update its antibody-drug conjugate forecast, pushing demand below the minimum supply agreed upon with CMOs and prompting the cancellation of an in-house investment.

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Uncategorized

New home for Novo’s Parkinson’s cell therapy; GSK turns to China for hep B drug

Published

on

Plus, label expansions for two drugs targeting rare diseases, and Genmab scraps a Phase 1 cancer trial:

🧠 Novo’s Parkinson’s cell therapy finds a biotech home: Novo Nordisk has found a home for an early-stage …

Continue Reading

Uncategorized

STAT+: Astellas treatment offers new hope to a devastated rare disease community

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

There’s fresh turmoil at the very top of the FDA: All weekend, questions have swirled over whether Commissioner Marty Makary will be ousted.

Also, we have a resurrected gene therapy effort in a once-devastated rare disease program, and underwhelming Alzheimer’s drug adoption. 

Continue to STAT+ to read the full story…

Read More

Published

on

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

There’s fresh turmoil at the very top of the FDA: All weekend, questions have swirled over whether Commissioner Marty Makary will be ousted.

Also, we have a resurrected gene therapy effort in a once-devastated rare disease program, and underwhelming Alzheimer’s drug adoption. 

Continue to STAT+ to read the full story…

Read More

Continue Reading

Uncategorized

Braveheart Bio’s Hengrui-licensed cardiac drug scores second clinical win

Published

on

Braveheart Bio said Monday that the heart muscle therapy it licensed from China’s Jiangsu Hengrui Pharmaceuticals has succeeded in a mid-stage trial for the same condition in which Cytokinetics recently scored a

Continue Reading
Advertisement

Trending